Product News: American Cyanamid's rotavirus vaccine
American Cyanamid's rotavirus vaccine: American Home Products applies Feb. 21 to divest American Cyanamid's human rotavirus vaccine research to Korea Green Cross to comply with the Federal Trade Commission's consent order approving the merger of AHP and American Cyanamid ("The Pink Sheet" Nov. 14, 1994, p. 11). Korea Green Cross also will be "the exclusive distributor in Korea of any oral rotavirus vaccine developed as a result of AHP's human rotavirus vaccine research program," AHP's application states. The public comment period on AHP's application will conclude March 25...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth